Screening and validation of serum protein biomarkers for early postmenopausal osteoporosis diagnosis

Wang,Long; Hu,Ya‑Qian; Zhao,Zhuo‑Jie; Zhang,Hong‑Yang; Gao,Bo; Lu,Wei‑Guang; Xu,Xiao‑Long; Lin,Xi‑Sheng; Wang,Jin‑Peng; Jie,Qiang; Luo,Zhuo‑Jing; Yang,Liu

doi:10.3892/mmr.2017.7620

Screening and validation of serum protein biomarkers for early postmenopausal osteoporosis diagnosis

Authors:
- Long Wang
- Ya‑Qian Hu
- Zhuo‑Jie Zhao
- Hong‑Yang Zhang
- Bo Gao
- Wei‑Guang Lu
- Xiao‑Long Xu
- Xi‑Sheng Lin
- Jin‑Peng Wang
- Qiang Jie
- Zhuo‑Jing Luo
- Liu Yang
View Affiliations

Affiliations: Institute of Orthopedic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: September 26, 2017 https://doi.org/10.3892/mmr.2017.7620
Pages: 8427-8433

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Postmenopausal osteoporosis is one of the most prominent worldwide public health problems and the morbidity is increasing with the aging population. It has been demonstrated that early diagnosis and intervention delay the disease progression and improve the outcome. Therefore, searching for biomarkers that are able to identify postmenopausal women at high risk for developing osteoporosis is an effective way to improve the quality of life of patients, and alleviate social and economic burdens. In the present study, a protein array was used to identify potential biomarkers. The bone mineral densities of 10 rats were dynamically measured in an ovariectomized model by micro‑computed tomography assessment, and the early stage of osteoporosis was defined. Through the protein array‑based screening, the expression levels of six serum protein biomarkers in ovariectomized rats were observed to alter at the initiation stage of the postmenopausal osteoporosis. Fractalkine, tissue inhibitor of metalloproteinases‑1 and monocyte chemotactic protein‑1 were finally demonstrated to be increased in the serum of eight enrolled postmenopausal osteoporosis patients using ELISA assay and were correlated with the severity of progressive bone loss. These biomarkers may be explored as potential early biomarkers to readily evaluate and diagnose postmenopausal osteoporosis in the clinic.

View Figures

View References

1	Kanis JA, Melton LJ III, Christiansen C, Johnston CC and Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res. 9:1137–1141. 1994. View Article : Google Scholar : PubMed/NCBI
2	Consensus development conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 94:646–650. 1993. View Article : Google Scholar : PubMed/NCBI
3	Mediati RD, Vellucci R and Dodaro L: Pathogenesis and clinical aspects of pain in patients with osteoporosis. Clin Cases Miner Bone Metab. 11:169–172. 2014.PubMed/NCBI
4	Nagae M, Hiraga T, Wakabayashi H, Wang L, Iwata K and Yoneda T: Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone. 39:1107–1115. 2006. View Article : Google Scholar : PubMed/NCBI
5	Roth T, Kammerlander C, Gosch M, Luger TJ and Blauth M: Outcome in geriatric fracture patients and how it can be improved. Osteoporos Int. 21 Suppl 4:S615–S619. 2010. View Article : Google Scholar : PubMed/NCBI
6	Rosen CJ: Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 353:595–603. 2005. View Article : Google Scholar : PubMed/NCBI
7	McCormick RK: Osteoporosis: Integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev. 12:113–145. 2007.PubMed/NCBI
8	Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, et al: Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. Osteoporos Int. 22:391–420. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kassahun K, McIntosh I, Koeplinger K, Sun L, Talaty JE, Miller DL, Dixon R, Zajic S and Stoch SA: Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 42:818–827. 2014. View Article : Google Scholar : PubMed/NCBI
10	Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, et al: Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 23:860–869. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE and Maeda N: Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 23:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Li L, Moore BT, Peng XH, Fang X, Lappe JM, Recker RR and Xiao P: MiR-133a in human circulating monocytes: A potential biomarker associated with postmenopausal osteoporosis. PLoS One. 7:e346412012. View Article : Google Scholar : PubMed/NCBI
13	Cao Z, Moore BT, Wang Y, Peng XH, Lappe JM, Recker RR and Xiao P: MiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis. PLoS One. 9:e970982014. View Article : Google Scholar : PubMed/NCBI
14	Cahill DJ: Protein and antibody arrays and their medical applications. J Immunol Methods. 250:81–91. 2001. View Article : Google Scholar : PubMed/NCBI
15	Senior K: Fingerprinting disease with protein chip arrays. Mol Med Today. 5:326–327. 1999. View Article : Google Scholar : PubMed/NCBI
16	Austen BM, Frears ER and Davies H: The use of seldi proteinchip arrays to monitor production of Alzheimer's betaamyloid in transfected cells. J Pept Sci. 6:459–469. 2000. View Article : Google Scholar : PubMed/NCBI
17	Park SB, Lee YJ and Chung CK: Bone Mineral Density Changes after Ovariectomy in Rats as an Osteopenic Model: Stepwise Description of Double Dorso-Lateral Approach. J Korean Neurosurg Soc. 48:309–312. 2010. View Article : Google Scholar : PubMed/NCBI
18	Yoshie O, Imai T and Nomiyama H: Chemokines in immunity. Adv Immunol. 78:57–110. 2001. View Article : Google Scholar : PubMed/NCBI
19	Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ and Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 91:521–530. 1997. View Article : Google Scholar : PubMed/NCBI
20	Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T and Patel DD: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion and activation under physiologic flow. J Exp Med. 188:1413–1419. 1998. View Article : Google Scholar : PubMed/NCBI
21	Han KH, Ryu JW, Lim KE, Lee SH, Kim Y, Hwang CS, Choi JY and Han KO: Vascular expression of the chemokine CX3CL1 promotes osteoclast recruitment and exacerbates bone resorption in an irradiated murine model. Bone. 61:91–101. 2014. View Article : Google Scholar : PubMed/NCBI
22	Koizumi K, Saitoh Y, Minami T, Takeno N, Tsuneyama K, Miyahara T, Nakayama T, Sakurai H, Takano Y and Nishimura M: Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J Immunol. 183:7825–7831. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hoshino A, Ueha S, Hanada S, Imai T, Ito M, Yamamoto K, Matsushima K, Yamaguchi A and Iimura T: Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts. J Cell Sci. 126:1032–1045. 2013. View Article : Google Scholar : PubMed/NCBI
24	Chen YD, Huang CY, Liu HY, Yao WF, Wu WG, Lu YL and Wang W: Serum CX3CL1/fractalkine concentrations are positively associated with disease severity in postmenopausal osteoporotic patients. Br J Biomed Sci. 73:121–128. 2016. View Article : Google Scholar : PubMed/NCBI
25	Rifas L, Fausto A, Scott MJ, Avioli LV and Welgus HG: Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: Differentiation is associated with repression of metalloproteinase biosynthesis. Endocrinology. 134:213–221. 1994. View Article : Google Scholar : PubMed/NCBI
26	Murphy E, Roux-Lombard P, Rooney T, Fitzgerald O, Dayer JM and Bresnihan B: Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis. Clin Rheumatol. 28:285–291. 2009. View Article : Google Scholar : PubMed/NCBI
27	Stanojkovic I, Kotur-Stevuljevic J, Spasic S, Milenkovic B, Vujic T, Stefanovic A and Ivanisevic J: Relationship between bone resorption, oxidative stress and inflammation in severe COPD exacerbation. Clin Biochem. 46:1678–1682. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ginaldi L, Di Benedetto MC and De Martinis M: Osteoporosis, inflammation and ageing. Immun Ageing. 2:142005. View Article : Google Scholar : PubMed/NCBI
29	Luo XH, Guo LJ, Shan PF, Xie H, Wu XP, Zhang H, Cao XZ, Yuan LQ and Liao EY: Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women. Osteoporos Int. 17:521–526. 2006. View Article : Google Scholar : PubMed/NCBI
30	Eraltan H, Cacina C, Kahraman OT, Kurt O, Aydogan HY, Uyar M, Can A and Cakmakoğlu B: MCP-1 and CCR2 gene variants and the risk for osteoporosis and osteopenia. Genet Test Mol Biomarkers. 16:229–233. 2012. View Article : Google Scholar : PubMed/NCBI